ELI LILLY AND COMPANY Cost of Goods Sold (Deprecated 2018-01-31)
ELI LILLY AND COMPANY (LLY) reported Cost of Goods Sold (Deprecated 2018-01-31) of $1.57 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-04-27
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.57B, a 16.57% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.62B, a 10.83% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.57B, a 11.79% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $1.55B, a 5.91% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $6.07B, a 7.34% increase from fiscal 2016.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $5.65B, a 12.26% increase from fiscal 2015.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $5.04B, a 2.12% increase from fiscal 2014.
- ELI LILLY AND COMPANY cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $4.93B, a 0.50% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $1.57B 10-Q · filed 2018-04-27 | $3.20B derived: sum of 2 quarters · filed 2018-04-27 | $4.76B derived: sum of 3 quarters · filed 2018-04-27 | $6.31B derived: sum of 4 quarters · filed 2018-04-27 | |
| 2017-12-31 | $1.62B 10-K · filed 2018-02-20 | $3.19B derived: sum of 2 quarters · filed 2018-02-20 | $4.74B derived: sum of 3 quarters · filed 2018-02-20 | $6.07B 10-K · filed 2018-02-20 | |
| 2017-09-30 | $1.57B 10-K · filed 2018-02-20 | $3.12B derived: sum of 2 quarters · filed 2018-02-20 | $4.45B 10-Q · filed 2017-10-27 | $5.93B derived: sum of 4 quarters · filed 2018-04-27 | |
| 2017-06-30 | $1.55B 10-K · filed 2018-02-20 | $2.88B 10-Q · filed 2017-07-28 | $4.37B derived: sum of 3 quarters · filed 2018-04-27 | $5.77B derived: sum of 4 quarters · filed 2018-04-27 | |
| 2017-03-31 | $1.35B 10-Q · filed 2018-04-27 | $1.33B 10-Q · filed 2017-05-01 | $2.81B derived: sum of 2 quarters · filed 2018-04-27 | $4.21B derived: sum of 3 quarters · filed 2018-04-27 | $5.68B derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $1.47B 10-K · filed 2018-02-20 | $2.87B derived: sum of 2 quarters · filed 2018-02-20 | $4.33B derived: sum of 3 quarters · filed 2018-02-20 | $5.65B 10-K · filed 2018-02-20 | |
| 2016-09-30 | $1.40B 10-K · filed 2018-02-20 | $2.87B derived: sum of 2 quarters · filed 2018-02-20 | $4.19B 10-Q · filed 2017-10-27 | $5.58B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-06-30 | $1.47B 10-K · filed 2018-02-20 | $2.79B 10-Q · filed 2017-07-28 | $4.18B derived: sum of 3 quarters · filed 2018-02-20 | $5.41B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-03-31 | $1.32B 10-K · filed 2018-02-20 | $2.71B derived: sum of 2 quarters · filed 2018-02-20 | $3.95B derived: sum of 3 quarters · filed 2018-02-20 | $5.17B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2015-12-31 | $1.39B 10-K · filed 2017-02-21 | $2.63B derived: sum of 2 quarters · filed 2017-02-21 | $3.84B derived: sum of 3 quarters · filed 2017-02-21 | $5.04B 10-K · filed 2018-02-20 | |
| 2015-09-30 | $1.24B 10-K · filed 2017-02-21 | $2.46B derived: sum of 2 quarters · filed 2017-02-21 | $3.65B 10-Q · filed 2016-10-28 | $4.90B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-06-30 | $1.22B 10-K · filed 2017-02-21 | $2.41B 10-Q · filed 2016-07-28 | $3.66B derived: sum of 3 quarters · filed 2017-02-21 | $4.93B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | $1.19B 10-K · filed 2017-02-21 | $2.45B derived: sum of 2 quarters · filed 2017-02-21 | $3.71B derived: sum of 3 quarters · filed 2017-02-21 | $4.90B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $1.25B 10-K · filed 2016-02-19 | $2.52B derived: sum of 2 quarters · filed 2016-02-19 | $3.71B derived: sum of 3 quarters · filed 2016-02-19 | $4.93B 10-K · filed 2017-02-21 | |
| 2014-09-30 | $1.27B 10-K · filed 2016-02-19 | $2.46B derived: sum of 2 quarters · filed 2016-02-19 | $3.68B 10-Q · filed 2015-10-30 | $5.07B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $1.19B 10-K · filed 2016-02-19 | $2.41B 10-Q · filed 2015-07-30 | $3.80B derived: sum of 3 quarters · filed 2016-02-19 | $5.00B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $1.22B 10-K · filed 2016-02-19 | $2.61B derived: sum of 2 quarters · filed 2016-02-19 | $3.81B derived: sum of 3 quarters · filed 2016-02-19 | $4.97B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $1.39B 10-K · filed 2015-02-19 | $2.58B derived: sum of 2 quarters · filed 2015-02-19 | $3.75B derived: sum of 3 quarters · filed 2015-02-19 | $4.91B 10-K · filed 2016-02-19 | |
| 2013-09-30 | $1.20B 10-K · filed 2015-02-19 | $2.36B derived: sum of 2 quarters · filed 2015-02-19 | $3.52B 10-Q · filed 2014-10-29 | $4.77B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-06-30 | $1.17B 10-K · filed 2015-02-19 | $2.32B 10-Q · filed 2014-07-28 | $3.57B derived: sum of 3 quarters · filed 2015-02-19 | $4.78B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-03-31 | $1.16B 10-K · filed 2015-02-19 | $2.41B derived: sum of 2 quarters · filed 2015-02-19 | $3.61B derived: sum of 3 quarters · filed 2015-02-19 | $4.76B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2012-12-31 | $1.25B 10-K · filed 2014-02-19 | $2.45B derived: sum of 2 quarters · filed 2014-02-19 | $3.60B derived: sum of 3 quarters · filed 2014-02-19 | $4.80B 10-K · filed 2015-02-19 | |
| 2012-09-30 | $1.20B 10-K · filed 2014-02-19 | $2.35B derived: sum of 2 quarters · filed 2014-02-19 | $3.55B 10-Q · filed 2013-10-30 | $4.87B derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-06-30 | $1.15B 10-K · filed 2014-02-19 | $2.34B 10-Q · filed 2013-07-26 | $3.67B derived: sum of 3 quarters · filed 2014-02-19 | $5.00B derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-03-31 | $1.20B 10-K · filed 2014-02-19 | $2.52B derived: sum of 2 quarters · filed 2014-02-19 | $3.86B derived: sum of 3 quarters · filed 2014-02-19 | $5.09B derived: sum of 4 quarters · filed 2014-02-19 | |
| 2011-12-31 | $1.32B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $2.66B derived: sum of 2 quarters · filed 2014-02-19 | $3.89B derived: sum of 3 quarters · filed 2014-02-19 | $5.07B 10-K · filed 2014-02-19 | |
| 2011-09-30 | $1.34B 10-Q · filed 2012-10-26 | $2.57B derived: sum of 2 quarters · filed 2012-10-26 | $3.75B 10-Q · filed 2012-10-26 | $4.98B derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-06-30 | $1.23B 10-Q · filed 2012-07-27 | $2.41B 10-Q · filed 2012-07-27 | $3.64B derived: sum of 3 quarters · filed 2013-02-21 | $4.63B derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-03-31 | $1.18B 10-Q · filed 2012-04-30 | $2.41B derived: sum of 2 quarters · filed 2013-02-21 | $3.40B derived: sum of 3 quarters · filed 2013-02-21 | $4.42B derived: sum of 4 quarters · filed 2013-02-21 | |
| 2010-12-31 | $1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $2.22B derived: sum of 2 quarters · filed 2013-02-21 | $3.24B derived: sum of 3 quarters · filed 2013-02-21 | $4.37B 10-K · filed 2013-02-21 | |
| 2010-09-30 | $987.60M 10-Q · filed 2011-10-28 | $2.01B derived: sum of 2 quarters · filed 2011-10-28 | $3.13B 10-Q · filed 2011-10-28 | $4.57B derived: sum of 4 quarters · filed 2012-02-24 | |
| 2010-06-30 | $1.02B 10-Q · filed 2011-07-29 | $2.15B 10-Q · filed 2011-07-29 | $3.58B derived: sum of 3 quarters · filed 2012-02-24 | $4.63B derived: sum of 4 quarters · filed 2012-02-24 | |
| 2010-03-31 | $1.12B 10-Q · filed 2011-04-29 | $2.55B derived: sum of 2 quarters · filed 2012-02-24 | $3.61B derived: sum of 3 quarters · filed 2012-02-24 | $4.55B derived: sum of 4 quarters · filed 2012-02-24 | |
| 2009-12-31 | $1.43B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $2.48B derived: sum of 2 quarters · filed 2012-02-24 | $3.43B derived: sum of 3 quarters · filed 2012-02-24 | $4.25B 10-K · filed 2012-02-24 | |
| 2009-09-30 | $1.05B 10-Q · filed 2010-10-29 | $2.00B derived: sum of 2 quarters · filed 2010-10-29 | $2.82B 10-Q · filed 2010-10-29 | $3.73B derived: sum of 4 quarters · filed 2011-02-22 | |
| 2009-06-30 | $947.40M 10-Q/A · filed 2010-08-02 | $1.76B 10-Q/A · filed 2010-08-02 | $2.67B derived: sum of 3 quarters · filed 2011-02-22 | $3.83B derived: sum of 4 quarters · filed 2011-02-22 | |
| 2009-03-31 | $816.40M 10-Q · filed 2010-07-30 | $1.73B derived: sum of 2 quarters · filed 2011-02-22 | $2.88B derived: sum of 3 quarters · filed 2011-02-22 | $4.08B derived: sum of 4 quarters · filed 2011-02-22 | |
| 2008-12-31 | $909.30M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22 | $2.06B derived: sum of 2 quarters · filed 2011-02-22 | $3.27B derived: sum of 3 quarters · filed 2011-02-22 | $4.38B 10-K · filed 2011-02-22 | |
| 2008-09-30 | $1.16B 10-Q · filed 2009-10-30 | $2.36B derived: sum of 2 quarters · filed 2009-10-30 | $3.47B 10-Q · filed 2009-10-30 | ||
| 2008-06-30 | $1.20B 10-Q · filed 2009-07-31 | $2.31B 10-Q · filed 2009-07-31 | |||
| 2007-12-31 | $4.25B 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |